

HR 6485

Skinny Labels, Big Savings Act

Congress: 119 (2025–2027, Current)

Chamber: House

Policy Area: Commerce

Introduced: Dec 5, 2025

Current Status: Referred to the House Committee on the Judiciary.

Latest Action: Referred to the House Committee on the Judiciary. (Dec 5, 2025)

Official Text: <https://www.congress.gov/bill/119th-congress/house-bill/6485>

Sponsor

Name: Rep. Cline, Ben [R-VA-6]

Party: Republican • **State:** VA • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Lofgren, Zoe [D-CA-18]	D · CA		Dec 5, 2025
Rep. Kiggans, Jennifer A. [R-VA-2]	R · VA		Apr 20, 2026
Rep. Suozzi, Thomas R. [D-NY-3]	D · NY		Apr 20, 2026

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	House	Referred To	Dec 5, 2025

Subjects & Policy Tags

Policy Area:

Commerce

Related Bills

Bill	Relationship	Last Action
119 S 43	Identical bill	Jan 9, 2025: Read twice and referred to the Committee on the Judiciary.

Skinny Labels, Big Savings Act

This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs.

Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in *GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.*, a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics.

The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act:

- submitting or seeking approval of a skinny label for a generic or biosimilar drug;
- promoting or commercially marketing a drug with skinny labeling approved by the FDA; or
- describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug.

The bill also applies the safe harbor to similar actions under the Public Health Service Act.

- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Introduced in House
- Dec 5, 2025: Referred to the House Committee on the Judiciary.